# Official Website: Rebel Medicine

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://www.rebelmedicine.com/
**Publisher:** Rebel Medicine Inc.
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

Rebel Medicine's official website describes the company as developing disruptive, non-opioid solutions for acute pain, with a lead asset Alevatrix™ positioned as a best-in-class long-acting local anesthetic for non-opioid postoperative pain management.

## Useful Claims

- The company states it is focused on developing disruptive, non-opioid solutions for acute pain.
- Rebel Medicine markets Alevatrix™ as a long-acting local anesthetic for non-opioid postoperative pain management.
- The site reports completion of a Pre-IND meeting for Alevatrix™ (September 30, 2024).
- The site reports publication of data from Alevatrix™ large-animal preclinical studies (August 6, 2024).
- The site reports NSF SBIR Phase 2b and NIH SBIR Phase 1 grant awards (October 11, 2023).
- Rebel Medicine is headquartered in Salt Lake City, Utah (per company press materials linked from the site).

## Reliability Notes

This is an official company source. Clinical-stage claims, regulatory milestones, and competitive positioning ("best-in-class") are company assertions and should be confirmed against FDA filings, peer-reviewed publications, and independent clinical data before being treated as high-confidence evidence. The site does not disclose detailed formulation science, trial timelines, or financing on the homepage.

## Related Pages

- [Rebel Medicine](rebel-medicine.md)